secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2021-10-12T23:59:59+00:00
Accession:  0001438533-21-000047
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CMO Noah Rosenberg to step down Dec 31, 2021; to serve as executive advisor through 2022
--------------------------------------------------------------------------------

- Noah Rosenberg will transition from CMO to executive advisor effective Dec 31, 2021.
- He will continue as CMO until year-end, then advise through 2022 on clinical trial oversight and regulatory submissions.
- Transition agreement provides severance benefits consistent with existing employment agreement.
- Post-transition consulting includes monthly retainer through May 2022, hourly fees June-Dec 2022, and success bonus tied to FDA acceptance of sparsentan NDA.
- Stock awards continue vesting; severance amendments extend certain benefits to 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853321000047/0001438533-21-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853321000047/tvtx-20211012.htm
  HTML page:      https://secwatch.observer/filing/0001438533-21-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer